Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (Note: Input metadata lists "Protara," but the filing text confirms "Proteon Therapeutics, Inc.")
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2019
Reporting Period: Second Quarter ended June 30, 2019
Status: Emerging Growth Company
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data points. It references a press release (Exhibit 99.1) for the actual figures.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It solely announces the issuance of the Q2 2019 financial results press release.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on August 7, 2019, announcing its financial results for the second quarter ended June 30, 2019.
Legal Disclaimer: The information in this Form 8-K under Item 2.02, including the attached exhibit, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that Section. It shall not be incorporated by reference into any registration statement unless expressly set forth by specific reference.
Guidance/Risks: No specific guidance, outlook, or risk factors are detailed in this cover sheet text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for actual revenue, net loss, and cash position figures.
- Confirm the company name is Proteon Therapeutics, Inc. (distinct from "Protara" in the request metadata).
- Review the press release for any updates on clinical trial progress or pipeline milestones, as this is a biopharmaceutical company.
- Check subsequent filings for any restatements or updates to the Q2 2019 results.